- Seagen Inc. sells three novel cancer agents—known as antibody drug conjugates, or ADCs—that work like a guided missile attacking tumors with toxins.
- Pfizer Inc. and Merck & Co. have had early-stage discussions about buying Seagen.
- Seagen has more than nine studies evaluating its ADCs with immunotherapies under way.
- The FDA is reviewing a regimen combining Padcev, an ADC from Seagen and Astellas Pharma Inc., with Merck's Keytruda immunotherapy for treatment of advanced bladder cancer.
- Seagen is also developing next-generation conjugates, including one that showed promise against lung tumors in an early-stage study.
WSJ — Business — Cancer Therapy — Drugs — Pharmaceuticals — Biotech
Seagen’s Cancer Therapy Is Making It a Takeover Target
Seagen Inc. sells novel cancer agents and is being targeted by big drugmakers, with the FDA reviewing a regimen combining Padcev with Merck's Keytruda immunotherapy for advanced bladder cancer.